Effects of early luteal phase vaginal progesterone supplementation on the outcome of in-vitro fertilization and embryo transfer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000200381

Enrollment

196

Registered

2008-04-14

Start date

2002-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Vaginal progesterone supplementation in early luteal phase after the treatment of in-vitro fertilization and embryo transfer (a total of nine doses of 200 mg micronized progesterone vaginally, three times daily commencing in the afternoon of oocyte retrieval till the morning of embryo transfer)

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

20 Years to 39 Years

Healthy volunteers

Inclusion criteria

women undergoing the treatment of in-vitro fertilization and embryo transfer, with HCG administration as the standard luteal phase support

Exclusion criteria

age = 40 year-old use of vaginal progesterone for luteal phase support because of risk of ovarian hyperstimulation syndrome distorted uterine cavity, e.g. due to submucosal fibroids or uterine anomalies

Outcome results